TT-702 is under clinical development by Teon Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TT-702’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TT-702 is under development for the treatment of solid tumor, metastatic castration resistant prostate cancer, triple negative breast cancer, melanoma and colorectal cancer. It is administered through oral route. The drug candidate acts by targeting adenosine receptor A2b.
Teon Therapeutics overview
Teon Therapeutics, is a biopharmaceutical company that discovers and develops small molecule drugs for cancer immunotherapy, cardiovascular and metabolic diseases. The company is headquartered in United States.
For a complete picture of TT-702’s drug-specific PTSR and LoA scores, buy the report here.